Trial · NCT01596335
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Defervescence Rate Within 48 Hours After the Start of the Study Drug Administration | TA-650 | 75.0 | percentage of patients | ||
| Defervescence Rate Within 48 Hours After the Start of the Study Drug Administration | Polyethylene Glycol-treated Human Immunoglobulin (VGIH) | 33.3 | percentage of patients | ||
| Duration of Fever | TA-650 | Duration since starting of drug administration | 16.00 | Inter-Quartile Range 7.70 to 38.75 | hour |
| Duration of Fever | Polyethylene Glycol-treated Human Immunoglobulin (VGIH) | Duration since starting of drug administration | 42.20 | Inter-Quartile Range 20.00 to 60.70 | hour |
| Duration of Fever | TA-650 | Duration since completing of drug administration | 13.90 | Inter-Quartile Range 5.90 to 36.50 | hour |
| Duration of Fever | Polyethylene Glycol-treated Human Immunoglobulin (VGIH) | Duration since completing of drug administration | 25.90 | Inter-Quartile Range 17.30 to 39.80 | hour |
| Incidence of Coronary Artery Lesions | TA-650 | Day 3 | 0 | percentage of patients | |
| Incidence of Coronary Artery Lesions | Polyethylene Glycol-treated Human Immunoglobulin (VGIH) | Day 3 | 12.5 | percentage of patients | |
| Incidence of Coronary Artery Lesions | TA-650 | Day 7 | 0 | percentage of patients | |
| Incidence of Coronary Artery Lesions | Polyethylene Glycol-treated Human Immunoglobulin (VGIH) | Day 7 | 14.3 | percentage of patients | |
| Incidence of Coronary Artery Lesions | TA-650 | Day14 | 0 | percentage of patients | |
| Incidence of Coronary Artery Lesions | Polyethylene Glycol-treated Human Immunoglobulin (VGIH) | Day14 | 16.7 | percentage of patients | |
| Incidence of Coronary Artery Lesions | TA-650 | Day 21 | 0 | percentage of patients | |
| Incidence of Coronary Artery Lesions | Polyethylene Glycol-treated Human Immunoglobulin (VGIH) | Day 21 | 20.0 | percentage of patients | |
| Incidence of Coronary Artery Lesions | TA-650 | Day56 | 0 | percentage of patients | |
| Incidence of Coronary Artery Lesions | Polyethylene Glycol-treated Human Immunoglobulin (VGIH) | Day56 | 0.0 | percentage of patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01596335/results